BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24643899)

  • 1. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
    Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
    Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers.
    Chang YL; Wu CT; Lin SC; Hsiao CF; Jou YS; Lee YC
    Clin Cancer Res; 2007 Jan; 13(1):52-8. PubMed ID: 17200338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.
    Takamochi K; Oh S; Matsuoka J; Suzuki K
    Lung Cancer; 2012 Mar; 75(3):313-20. PubMed ID: 22209037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
    Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread.
    Chung JH; Choe G; Jheon S; Sung SW; Kim TJ; Lee KW; Lee JH; Lee CT
    J Thorac Oncol; 2009 Dec; 4(12):1490-5. PubMed ID: 19844187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
    Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
    Lee JS; Kim HR; Lee CY; Shin M; Shim HS
    Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
    Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
    Girard N; Deshpande C; Azzoli CG; Rusch VW; Travis WD; Ladanyi M; Pao W
    Chest; 2010 Jan; 137(1):46-52. PubMed ID: 19376842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
    J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure.
    Arrieta O; Campos-Parra AD; Zuloaga C; Avilés A; Sánchez-Reyes R; Manríquez ME; Covián-Molina E; Martínez-Barrera L; Meneses A; Cardona A; Borbolla-Escoboza JR
    J Thorac Oncol; 2012 Aug; 7(8):1228-34. PubMed ID: 22659961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.